---
title: "BioCardia IncQ) expected to post a loss of 50 cents a share - Earnings Preview"
description: "BioCardia IncQ) is anticipated to report a loss of 50 cents per share for the quarter ending June 30, 2025, with a decline in revenue. The sole analyst rating is a \"buy,\" and the mean earnings estimat"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/252242449.md"
published_at: "2025-08-08T12:52:19.000Z"
---

# BioCardia IncQ) expected to post a loss of 50 cents a share - Earnings Preview

> BioCardia IncQ) is anticipated to report a loss of 50 cents per share for the quarter ending June 30, 2025, with a decline in revenue. The sole analyst rating is a "buy," and the mean earnings estimate has remained unchanged over the past three months. Wall Street's median 12-month price target for the company is $15.50, representing a potential increase of 89.2% from its last closing price of $1.68.

-   BioCardia Inc (BCDA.OQ) (BCDA.O) is expected to show a fall in quarterly revenue when it reports results on August 11 for the period ending June 30 2025
-   ​LSEG’s mean analyst estimate for BioCardia Inc is for a loss of 50 cents per share.
-   The one available analyst rating on the shares is “buy”.
-   The mean earnings estimate of analysts was unchanged in the last three months. ​
-   Wall Street’s median 12-month price target for BioCardia Inc is $15.50, about 89.2% above its last closing price of $1.68 This summary was machine generated August 8 at 12:52 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

### Related Stocks

- [BCDA.US - BioCardia](https://longbridge.com/en/quote/BCDA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| BioCardia 为 Helix™提交了 FDA 批准的预提交文件 | BioCardia Inc：BioCardia 提交了 Helix™ 经心内膜输送导管的预提交申请，以获得 FDA 对心脏治疗和诊断药物输送的批准 | [Link](https://longbridge.com/en/news/275481248.md) |
| BioCardia 展示了 CardiAMP-HF 研究中的新超声心动图数据 | BioCardia Inc. 宣布，心力衰竭细胞治疗的 CardiAMP HF 临床试验的新超声心动图结果已被接受，在技术与心力衰竭治疗会议（THT Meeting）上进行晚期临床试验口头报告。该报告题为 “自体细胞治疗可能抑制慢性缺血性  | [Link](https://longbridge.com/en/news/274660260.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.